“We made significant progress in 2024, highlighted by initial CMS reimbursement for our Ekso Indego Personal,” said Scott Davis, the Company’s Chief Executive Officer. “With expanded access of this transformative device to Medicare-covered patients, we remain focused on building upon our growing CMS claim pipeline. At the same time, we continue to bolster demand for our flagship EksoNR device as we execute on our long-term growth strategy.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EKSO:
- Ekso Bionics to showcase device technology in ‘AI for Good’ Webinar